'24e-'26e ARR cut by 2-3% on continued macro weakness B2C business momentum likely to return in H2'2...
Solid Q1 with 33% ARR growth and 15% adj. EBITDA margin Raising '24e-'26e ARR by ~1%, EBITDA by 19-1...
Försäljningen i Q4 minskade något jämfört med samma period i fjol.
Inför Q1: marknadsdata indikerar underliggande tillväxt i Sverige Vi förväntar oss en omsättningstil...
Q1: 33% y-o-y ARR growth and 15% adj. EBITDA margin All FY'24 guidance items upgraded once again Con...
The recorded sales growth is 0% in local currency due to an extended headwind for the Genetics busin...
SRV publishes its Q1/24 figures on Thursday 25th of April.
Consti reports its Q1/24 results on 25th of April. We expect continued sales decline during the seas...
Redeye leaves an initial comment following the Q1 report published by Magle this morning.
Redeye provides its initial take on Vitec’s Q1 2024 report, which came in slightly below our estimat...
Redeye provides its initial take on ADDvise’s Q1 2024 report, which came in broadly below our estima...
Hansa’s Q1 result includes a positive outlook in 2024 supported by additional countries and the Euro...
We lower '24e-'26e adj. EBITA by 10-3%... ...on continued weakness in macro data '24e EV/EBITA of ~8...
Positive order intake momentum Outdoor demand rebound during Q3e '24e-'26e EBIT up 3-2% Positive mo...
Q1e sales SEK 43m, down 2% y-o-y, adj. EBIT SEK 0m (0m) Tough comps due to Duni product-launch inven...
Q1e sales SEK 33.2m, up 25% y-o-y, EBIT margin 33.8% (24.
Redeye briefly comments on Circio’s rights issue. We pause our coverage.
Sales +7% and EBIT +11% vs. ABGSCe Organic growth of +10%, better than ABGSCe +3% Order bookings bea...
Redeye reinforces its view of Vertiseit following a solid Q1 report, with slightly higher ARR growth...
Raute reports Q1 results on May 3. We estimate earnings to improve over the course of the year, driv...